Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV

Arbutus Biopharma Corp

First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.
Arm evaluates low-dose nivolumab plus VTP-300 boosters after AB-729 and NA therapy to reduce HBsAg in chronic HBV.
Preliminary data from this arm expected in 2024; original arm data expected H2 2023.
Enrollment complete in original arm; approximately 20 patients to be enrolled in new open-label arm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.